Autoimmune lymphoproliferative syndrome screening

Autoimmune lymphoproliferative syndrome Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune lymphoproliferative syndrome screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune lymphoproliferative syndrome screening
CDC on Autoimmune lymphoproliferative syndrome screening
Autoimmune lymphoproliferative syndrome screening in the news
Blogs on Autoimmune lymphoproliferative syndrome screening
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

There is insufficient evidence to recommend routine screening for [disease/malignancy].

OR

According to the [guideline name], screening for [disease name] is not recommended.

OR

According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].